The success of VEGF-inhibition in second-line combination chemotherapy + ICI therapy for EGFRm NSCLC patients with PD on EGFR TKI is one of the few bright signals currently in the field, and we eagerly await the results of current trials that are ongoing further exploring this question (Table 3). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.